Physician profile
Julia H Barton
NPI 1609193093
$10,027.21
in general payments reported to CMS, 2019-2025
44 companies · $1,538 in 2025
The $1,538 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $751 · 2020: $350 · 2021: $708 · 2022: $1,368 · 2023: $3,708 · 2024: $1,605 · 2025: $1,538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,605 · Travel and Lodging: $1,175 · Education: $71.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,604.92 |
| Travel and Lodging | $1,174.58 |
| Education | $71.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Respicardia, INC. | $2,734.62 | 2022-2025 | Remede System |
| Glaxosmithkline, LLC. | $1,141.41 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $862.22 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $752.72 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Harmony Biosciences LLC | $607.06 | 2021-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $408.81 | 2020-2025 | |
| Genentech USA, INC. | $299.95 | 2019-2024 | Xolair |
| Genzyme Corporation | $252.00 | 2021-2025 | |
| Insmed, INC. | $232.15 | 2019-2025 | Arikayce |
| Alexion Pharmaceuticals, INC. | $219.99 | 2019-2022 | |
| Mylan Specialty L.P. | $204.45 | 2019-2024 | Yupelri |
| United Therapeutics Corporation | $195.32 | 2021-2025 | Tyvaso, Tyvaso |
| La Jolla Pharmaceutical Company | $195.02 | 2020-2023 | Giapreza |
| Merck Sharp & Dohme LLC | $192.93 | 2023-2025 | Zerbaxa, Recarbrio |
| Takeda Pharmaceuticals U.S.A., INC. | $183.93 | 2020-2025 | Glassia |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $175.97 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $171.21 | 2022-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $150.78 | 2019-2024 | Opsumit, Uptravi |
| Philips North America LLC | $120.73 | 2019-2022 | |
| Pfizer INC. | $113.90 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $103.21 | 2022-2023 | Acthar |
| Baxter Healthcare | $93.94 | 2022-2024 | Hillrom - Monarch Airway Clearance System, Hillrom - Synclara Cough System, Hillrom - Metaneb System |
| Ani Pharmaceuticals, INC. | $73.22 | 2023-2025 | Purified Cortrophin Gel |
| Abbvie INC. | $69.93 | 2022-2025 | Avycaz |
| Amgen INC. | $50.45 | 2022-2025 | Tezspire |
| Avadel Cns Pharmaceuticals, LLC | $46.39 | 2025 | Lumryz |
| Bayer Healthcare Pharmaceuticals INC. | $41.54 | 2022 | |
| Edwards Lifesciences Corporation | $39.03 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Axsome Therapeutics, INC. | $36.45 | 2023 | Sunosi |
| Viatris Specialty LLC | $21.75 | 2025 | Yupelri |
| Verona Pharma, INC. | $21.12 | 2025 | Ohtuvayre |
| Portola Pharmaceuticals, LLC | $20.91 | 2019 | |
| Mallinckrodt Enterprises LLC | $20.60 | 2019 | |
| Bioxcel Therapeutics, INC. | $19.31 | 2023 | Igalmi |
| Lilly USA, LLC | $18.61 | 2025 | Zepbound |
| Paratek Pharmaceuticals, INC. | $17.27 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $16.71 | 2019 | |
| Boston Scientific Corporation | $16.35 | 2024 | Rezum Generator |
| Inspire Medical Systems, INC. | $15.17 | 2024 | Inspire |
| Uswm, LLC | $15.00 | 2021 | |
| Vapotherm INC | $14.43 | 2022 | |
| Fisher & Paykel Healthcare INC | $14.32 | 2023 | Fisher & Paykel Healthcare |
| Applied Medical Technology INC | $14.11 | 2019 | |
| Grifols USA, LLC | $12.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Barton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.